Analysts rate Exactech shares — 5 facts

During the most recent broker reports, one analyst gave Exactech shares a “buy” rating, according to Share Trading.

Advertisement

Here are five facts:

 

1. One analyst gave the shares an “outperform” rating and two analysts gave the shares a “hold” rating.

 

2. No analysts rated the shares as “underperform” or “sell.”

 

3.  Northland Securities reiterated Exactech shares’ “market perform” rating on Oct. 28, 2015.

 

4. Exactech has a 50-day moving average of $18.79 and a 200-day moving average of $18.32.

 

5. The market cap is nearly $281.4 million.

 

More articles on devices:
Beyond the device: How DePuy Synthes is innovating in orthopedic & spine technology
UW Medicine’s orthopedics & urology departments to implement C-SATS — 5 things to know
LDR, Xtant Medical, Smith & Nephew & more: 14 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.